Clinical trials: Colon Neoplasia
Colon Cancer Stage I
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post…
- Trial name
- NCT05394714
- Testing
- Magicell-NK contains NK cells suspended in 100 mL normal saline
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Medigen Biotechnology Corporation
Colon Cancer, Metastatic Colon Cancer
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors…
- Trial name
- NCT05848739
- Testing
- ST316, FOLFIRI regimen & bevacizumab, Fruquintinib
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sapience Therapeutics
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Liver Metastasis Colon Cancer
Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools
This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.
- Trial name
- PSMA (NCT06935149)
- Testing
- 18-PSMA
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Primo Biotechnology Co., Ltd
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Colon Neoplasms, Crohn Disease (CD)
Feasibility Study of the SEGER Device in Laparoscopic Gastrointestinal Surgery
This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
- Conditions
- Colon Neoplasms, Crohn Disease (CD), Obesity & Overweight
- Trial name
- SEGER-FIH (NCT07508592)
- Testing
- SEGER Device
- Where
- El Salvador
- Volunteers
- 10 people
- Sponsor
- Seger Surgical Solutions
Fatigue Related to Cancer Treatment, Colon Cancer
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.
- Trial name
- NuvastaticTM (NCT07669454)
- Testing
- Nuvastatic 300
- Where
- 6 sites in India
- Volunteers
- 250 people
- Sponsor
- Natureceuticals Sdn Bhd
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Anastomotic Leak, Colon Cancer
Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy
The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to…
- Conditions
- Anastomotic Leak, Colon Cancer, Right Hemicolectomy
- Trial name
- LICOSARH (NCT07132970)
- Testing
- Monoplus Suture Material
- Where
- 4 sites in Germany
- Volunteers
- 249 people
- Sponsor
- Aesculap AG
Annual Wellness Visit, Breast Cancer Screening
Messaging Intervention to Increase Medicare Annual Wellness Visits -- The NUDGE AWV Clinical Trial
Medicare Annual Wellness Visits (AWVs) are critical for addressing preventive care needs among older adults, yet the most recent estimates from the Center for Medicare Services suggest less than 50% of eligible patients take…
- Conditions
- Annual Wellness Visit, Breast Cancer Screening, Colon Cancer Screening
- Trial name
- NCT06640426
- Testing
- Two Messaging Nudges, Five messaging nudges
- Where
- United States
- Volunteers
- 29,842 people, healthy volunteers welcome
- Sponsor
- Laura Feemster
Colon Cancer Screening
Patient Reminders Optimizing Mail-in Prevention Testing for Colorectal Cancer
Screening is an important tool for early colorectal cancer detection, and the most recent evidence suggests that early detection significantly improves survival rates.
- Trial name
- PROMPT-CRC (NCT06710509)
- Testing
- Three Messaging Nudges
- Where
- United States
- Volunteers
- 2,106 people
- Sponsor
- Laura Feemster
Colon Cancer Patients
Spectral Precise Image-Colon Cancer
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.
- Trial name
- NCT07620444
- Testing
- This is an observational study
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Liver Cancer, Liver Metastasis Colon Cancer
Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing
This will be a prospective, observational, cohort study to determine the impact of integrated diagnostics using quantitative magnetic resonance imaging, whole genome sequencing and digital pathology on intended patient management…
- Trial name
- Precision1 (NCT04597710)
- Testing
- utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Perspectum
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Neoplasms, Colon
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if…
- Trial name
- AZUR-4 (NCT06567782)
- Testing
- Dostarlimab, CAPEOX
- Where
- 33 sites in Belgium, Italy and 4 more
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Colorectal (Colon or Rectal) Cancer
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)
- Trial name
- NCT07462143
- Testing
- RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin
- Where
- 19 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
- Trial name
- NCT07412613
- Testing
- Cadonilimab (AK104), Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Akeso